Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, Seekins D, Krishna G, Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N. Regev A, et al. Among authors: dimick santos l. Aliment Pharmacol Ther. 2019 Mar;49(6):702-713. doi: 10.1111/apt.15153. Epub 2019 Feb 13. Aliment Pharmacol Ther. 2019. PMID: 30761572 Free PMC article. Review.
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N. Palmer M, et al. Among authors: dimick santos l. Aliment Pharmacol Ther. 2020 Jan;51(1):90-109. doi: 10.1111/apt.15579. Epub 2019 Nov 25. Aliment Pharmacol Ther. 2020. PMID: 31762074 Free PMC article. Review.
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Treem WR, et al. Among authors: dimick santos l. Drug Saf. 2021 Feb;44(2):133-165. doi: 10.1007/s40264-020-01014-2. Epub 2020 Nov 3. Drug Saf. 2021. PMID: 33141341 Free PMC article. Review.
Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.
Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Sanyal AJ, et al. Hepatology. 2015 Apr;61(4):1392-405. doi: 10.1002/hep.27678. Epub 2015 Mar 19. Hepatology. 2015. PMID: 25557690 Free PMC article.
Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum.
Noureddin M, Chan JL, Barradas K, Dimick-Santos L, Schabel E, Omokaro SO, Anania FA, Myers RP, Miller V, Sanyal AJ, Chalasani N; Liver Forum NASH Cirrhosis Working Group. Noureddin M, et al. Among authors: dimick santos l. Gastroenterology. 2020 Aug;159(2):422-427.e1. doi: 10.1053/j.gastro.2020.04.039. Epub 2020 Apr 27. Gastroenterology. 2020. PMID: 32353369 No abstract available.
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.
Hey-Hadavi J, Seekins D, Palmer M, Coffey D, Caminis J, Abdullaev S, Patwardhan M, Tyler H, Raheja R, Stanley AM, Pineda-Salgado L, Bourdet DL, Andrade RJ, Hayashi PH, Dimick-Santos L, Rockey DC, Estilo A. Hey-Hadavi J, et al. Among authors: dimick santos l. Drug Saf. 2021 Jun;44(6):619-634. doi: 10.1007/s40264-021-01051-5. Epub 2021 Mar 16. Drug Saf. 2021. PMID: 33725335 Free PMC article. Review.
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
Patel YA, Imperial JC, Muir AJ, Anstee QM, DeBrota D, Dimick-Santos L, Filozof C, Mehta R, Sanyal AJ, Schabel E, Neuschwander-Tetri BA, Miller V; Liver Forum’s Data Standardization Working Group. Patel YA, et al. Gastroenterology. 2017 Sep;153(3):621-625.e7. doi: 10.1053/j.gastro.2017.07.024. Epub 2017 Jul 27. Gastroenterology. 2017. PMID: 28757264 Free PMC article. No abstract available.
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.
Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ; Liver Forum Case Definitions Working Group. Siddiqui MS, et al. Hepatology. 2018 May;67(5):2001-2012. doi: 10.1002/hep.29607. Epub 2018 Feb 22. Hepatology. 2018. PMID: 29059456 Free PMC article.
13 results